Further, we demonstrate that addition of recombinant SDF-1 to the lung and bone lysates in the lower chamber reversed the effect of anti-IL-17A treatment and significantly increased the migration of the 4 T1 and PyV MT tumor cells towards the lower chamber (compare bar# 3 to bar# 4 in Figures 5C-F). Here, IL17A is linked to neoplasm.